- Home
- TGL vs INDP Comparison
TGL vs INDP Comparison
Compare TGL & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGL
- INDP
- Stock Information
- Founded
- TGL 2020
- INDP 2000
- Country
- TGL United States
- INDP United States
- Employees
- TGL N/A
- INDP N/A
- Industry
- TGL Retail: Computer Software & Peripheral Equipment
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- TGL Technology
- INDP Health Care
- Exchange
- TGL Nasdaq
- INDP Nasdaq
- Market Cap
- TGL 4.1M
- INDP 4.0M
- IPO Year
- TGL 2022
- INDP N/A
- Fundamental
- Price
- TGL $0.74
- INDP $3.45
- Analyst Decision
- TGL
- INDP Strong Buy
- Analyst Count
- TGL 0
- INDP 1
- Target Price
- TGL N/A
- INDP $140.00
- AVG Volume (30 Days)
- TGL 5.5M
- INDP 532.3K
- Earning Date
- TGL 10-15-2025
- INDP 11-07-2025
- Dividend Yield
- TGL N/A
- INDP N/A
- EPS Growth
- TGL N/A
- INDP N/A
- EPS
- TGL N/A
- INDP N/A
- Revenue
- TGL $2,330,557.00
- INDP N/A
- Revenue This Year
- TGL N/A
- INDP N/A
- Revenue Next Year
- TGL N/A
- INDP N/A
- P/E Ratio
- TGL N/A
- INDP N/A
- Revenue Growth
- TGL N/A
- INDP N/A
- 52 Week Low
- TGL $0.70
- INDP $2.22
- 52 Week High
- TGL $39.00
- INDP $47.60
- Technical
- Relative Strength Index (RSI)
- TGL 35.68
- INDP 44.84
- Support Level
- TGL $0.73
- INDP $3.41
- Resistance Level
- TGL $1.17
- INDP $3.76
- Average True Range (ATR)
- TGL 0.10
- INDP 0.44
- MACD
- TGL -0.02
- INDP 0.02
- Stochastic Oscillator
- TGL 6.33
- INDP 13.04
About TGL Treasure Global Inc.
Treasure Global Inc has created an online-to-offline e-commerce platform business model offering consumers and merchants instant rebates and affiliate cashback programs, while providing a seamless e-payment solution with rebates in both e-commerce and physical retailers/merchant settings. Its product is an internet application branded ZCITY app, that targets consumers by providing personalized deals based on consumers' purchase history, location and preferences.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.